US EditionABVC BioPharma Strengthens Investment in AiBtl BioPharma with Equity Conversion and Future Funding Commitment
Summary by Evertise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
ABVC BioPharma Strengthens Investment in AiBtl BioPharma with Equity Conversion and Future Funding Commitment
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the conversion of a $100,000 convertible note into 10,000 shares of common stock in AiBtl BioPharma Inc. at a conversion price of $10 per share, backed by an independent third-party valuation. This move underscores ABVC’s commitment to AiBtl, with plans to invest up to $20 million over time to support AiBtl’s licensing obligations and collaboration with global pharma…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
